Dataset Information

Discovery and validation of biomarkers for Parkinson’s disease from human cerebrospinal fluid using mass spectrometry-based proteomics analysis

ABSTRACT: Proteomic biomarkers for Parkinsons disease (PD) are critical for identifying new targets for disease modifying therapies and expanding our understanding of the disease pathophysiology.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cerebrospinal Fluid

DISEASE(S): Parkinson's Disease

SUBMITTER: chanhyun na

LAB HEAD: Chan-hyun Na

PROVIDER: PXD055996 | Pride | 2025-09-01

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 203

Publications

Discovery and validation of biomarkers for Parkinson's disease from human cerebrospinal fluid using mass spectrometry-based proteomics analysis.

Oh Sungtaek S Jung Jaehun J Kim Jinhyeok J Jang Yura Y Bakker Catherine C CC Pantelyat Alexander Y AY Zhang Zhen Z Dawson Ted M TM Na Chan Hyun CH Rosenthal Liana S LS

EBioMedicine 20250805

<h4>Background</h4>Proteomic biomarkers for Parkinson's disease (PD) are critical for identifying new targets for disease-modifying therapies and expanding our understanding of disease pathophysiology.<h4>Methods</h4>Deep proteome analysis of a cerebrospinal fluid (CSF) cohort (40 PD, 40 controls) coupled with previous data from the substantia nigra (SN) proteome was used to discover low abundance biomarkers involved in PD pathogenesis. We validated our findings using parallel reaction monitorin ...[more]

PMID: 40753721

Similar Datasets

Project description:Intense immunosuppression followed by autologous hematopoietic stem cell transplantation (aHSCT) is a potential treatment for patients suffering from aggressive multiple sclerosis (MS). However it remains unresolved whether autologous CD34+ hematopoietic progenitor cells of MS patients show gene expression differences prior to aHSCT that indicate a preset proinflammatory state, which would then also predispose to or predetermine recurrence of the autoimmune disease. To approach this key point we compared the gene expression signature of CD34+ and CD34- cells collected from MS patients and healthy donors (HD). Whole genome gene expression of CD34+ and CD34- cells was analysed with the Human 4x44K Design Array (Agilent-Technologies). As main observation we found only minor differences in the gene expression signature of MS patients compared to HD. Only a single gene, troponin-type-1 (TNNT1), reached statistical significance after correction for multiple comparisons (logFC=3.1, p<0.01). There was a decreased expression of several protease genes, myeloperoxidase (MPO), neutrophil-elastase (ELA2), cathepsin-G (CTSG) and serine-protease 21 (PRSS21) in HPCs of MS patients, albeit not reaching statistical significance. In summary we did not detect substantial alterations in the gene expression profile of CD34+ HPCs in MS. Our data support the use of autologous hematopoietic stem cell transplantation for treatment of an autoimmune disease. Samples of CD34+ cells were obtained from 4 female MS patients and 4 age matched healthy donors (3 female) mobilized by G-CSF (2x5M-NM-<g/kg/day) and 4 MS patients (2 female) mobilized by G-CSF (5M-NM-<g/kg/day) plus Cyclophosphamide (Cy, 4g/m2). White blood cells, containing the CD34+ cell fraction, were collected by leucocytapheresis from peripheral blood, frozen and stored in liquid nitrogen. All samples were thawed and processed at one center and CD34+ HPCs purified by magnetic bead separation using the autoMACS system (Miltenyi). Purity and viability of CD34+ cells was analyzed by Fluorescence Activated Cell Sorter (FACS). Total cellular RNA were extracted with TRIzol reagent and analyzed with the Human 4x44K Design Array (Agilent-Technologies).

			Action	DRS
	PD_CSF_Group1_FN01.raw	Raw
	PD_CSF_Group1_FN02.raw	Raw
	PD_CSF_Group1_FN03.raw	Raw
	PD_CSF_Group1_FN04.raw	Raw
	PD_CSF_Group1_FN05.raw	Raw